细胞周期检查点激酶1抑制剂的研究进展

孙琦,杨晓虹,董雷,刘安,王文娜孙薇

中国药学杂志 ›› 2013, Vol. 48 ›› Issue (22) : 1902-1907.

PDF(2854 KB)
PDF(2854 KB)
中国药学杂志 ›› 2013, Vol. 48 ›› Issue (22) : 1902-1907. DOI: 10.11669/cpj.2013.22.004
综述

细胞周期检查点激酶1抑制剂的研究进展

  • 孙琦1,杨晓虹1,1,2,刘安1,王文娜1,孙薇1*
作者信息 +

Progress in the Study of Cell Cycle Checkpoint Kinase 1 Inhibitors

  • SUN Qi1, YANG Xiao-hong1, DONG Lei1,2, LIU An1, WANG Wen-na1, SUN Wei1*
Author information +
文章历史 +

摘要

目的 综述近年来细胞周期检查点激酶1(cell cycle checkpoint kinase 1, Chk1)抑制剂的研究进展。 方法 通过对国内外相关文献进行查阅、归纳和总结,较为全面地介绍了细胞周期检查点激酶1抑制剂的研究现状。 结果与讨论 细胞周期检查点激酶1抑制剂与DNA损伤试剂联用具有良好的抗肿瘤疗效,随着细胞周期检查点激酶1抑制剂作用机制及构效关系研究的不断深入,细胞周期检查点激酶1抑制剂会有更广阔的发展前景,为癌症的治疗发挥更重要的作用。

Abstract

To review the recent research advances on the cell cycle checkpoint kinase 1 (Chk1) inhibitors. METHODS Through searching and summarying literatures of domestic and abroad, the research progress of the Chk1 inhibitors were introduced comprehensively. RESULTS AND CONCLUSION Chk1 inhibitors combining with DNA damaging agents have better antitumor efficacy. With the deepening studies on the Chk1 inhibitors and their structureactivity relationship, Chk1 inhibitors will have broader development prospects and play more important roles in the treatment of cancer.

关键词

细胞周期检查点激酶1 / 细胞周期检查点激酶1抑制剂 / 构效关系

Key words

cell cycle checkpoint kinase 1 / cell cycle checkpoint kinase 1 inhibitors / structure activity relationship

引用本文

导出引用
孙琦,杨晓虹,董雷,刘安,王文娜孙薇. 细胞周期检查点激酶1抑制剂的研究进展[J]. 中国药学杂志, 2013, 48(22): 1902-1907 https://doi.org/10.11669/cpj.2013.22.004
SUN Qi,YANG Xiao-hong,DONG Lei, LIU An,WANG Wen-na,SUN Wei. Progress in the Study of Cell Cycle Checkpoint Kinase 1 Inhibitors[J]. Chinese Pharmaceutical Journal, 2013, 48(22): 1902-1907 https://doi.org/10.11669/cpj.2013.22.004

参考文献

[1] SCHWARTZ G K, SHAH M A. Targeting the cell cycle: A new approach to cancer therapy. J Clin Oncol, 2005, 23(36): 9408-9421.[2] LOFFLER H, BOCHTLER T, FRITZ B, et al. DNA Damage-induced accumulation of centrosomal Chk1 contributes to its checkpoint function . Cell Cycle, 2007, 6(20): 2541-2548.[3] ZHOU B B, BARTEK J. Targeting the checkpoint kinases: Chemosensitization versus Chemoprotection . Cancer Rev, 2004, 4(3): 216-225.[4] KAWABE T. G2 checkpoint abrogators as anticancer drugs . Mol Cancer Ther, 2004, 3(4): 513-519.[5] GRAVES P R, LOVLY C M, UY G L, et al. Localization of human Cdc25C is regulated both by nuclear export and 14-3-3 protein binding . Oncogene, 2001, 20(15): 1839-1851.[6] POWELL S N, DEFRANK J S, CONNELL P, et al. Differential sensitivity of p53(-) and p53(+) cells to caffeine-induced radiosensitization and override of G2 delay . Cancer Res, 1995, 55(8): 1643-1648.[7] CONVERSO A, HARTINQH T, GARBACCIO R M, et al. Development of thioquinazolinones, allosteric Chk1 kinase inhibitors . Bioorg Med Chem Lett, 2009, 19(4): 1240-1244.[8] SAUSVILLE E A, LUSH R D, HEADLEE D, et al. Clinical pharmacology of UCN-01: Initial observations and comparison to preclinical models . Cancer Chemother Pharmacol, 1998, 42(Suppl): 54-59.[9] BLASINA A, HALLIN J, CHEN E, et al. Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1 . Mol Cancer Ther, 2008, 7(8): 2394-2404. ZABLUDOFF S D, DENG C, GRONDINE M R, et al. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies . Mol Cancer Ther, 2008, 7(9): 2955-2966. YOSHINARI T, MATSUMOTO M, ARAKAWA H, et al. Novel antitumor indolocarbazole compound 6-Nformylamino-12,13-dihydro-1,11-dihydroxy-13-(b-D-glucopyranosyl)5H-indolopyrrolocarbazole-5,7-(6H)-dione(NB-506): Induction of topoisomerase I mediated DNA cleavage and mechanism of cell line-selective cytotoxicity . Cancer Res, 1995, 55(6): 1310-1315. ARAKAWA H, MORITA M, KODERA T, et al. In vivo anti-tumor activity of a novel indolocarbazole compound, J-107088, on murine and human tumors transplanted into mice . Cancer Res, 1999, 90(10): 1163–1170. CONCHON E , ANIZON F, GOLSTEYN R M, et al. Synthesis, in vitro antiproliferative activities, and Chk1 inhibitory properties of dipyrrolocarbazole-triones . Tetrahedron, 2006, 62(48): 11136-11144. CONCHON E, ANIZON F, ABOAB B, et al. Synthesis, in vitro antiproliferative activities, and Chk1 inhibitory properties of pyrrolocarbazole-1,3-diones,pyrrolo-1,3-diones, and 2-aminopyridazinopyrrolocarbazole-1,3,4,7-tetraone . Med Chem, 2008, 43(2): 282-292. LEFOIX M, COUDERT G, ROUTIER S, et al. Novel 5-azaindolocarbazoles as cytotoxic agents and Chk1 inhibitors . Bioorg Med Chem, 2008, 16(9): 5303-5321. LIN N H, XIA P, KOVAR P, et al. Synthesis and biological evaluation of 3-ethylidene-1,3-dihydroindol-2-ones as novel checkpoint 1 inhibitors . Bioorg Med Chem Lett,2006, 16(2): 421-426. GARBACCIO R M, HUANG S, TASBER E S, et al. Synthesis and evaluation of substituted benzoisoquinolinones as potent inhibitors of Chk1 kinase . Bioorg Med Chem Lett,2007,17(22), 6280-6285. BRNARDIC E J, GARBACCIO R M, FRALEY M E, et al. Optimization of a pyrazoloquinolinone class of Chk1 kinase inhibitors . Bioorg Med Chem Lett,2007, 17(21): 5989-5994. TAO Z F, LI G Q, TONG Y S, et al. Synthesis and biological evaluation of4′-(6,7-diSubstituted-2,4-dihydro-indenopyrazol-3-yl)-biphenyl-4-ol as potent Chk1 inhibitors. Bioorg Med Chem Lett,2007, 17(15): 4308-4315. LI G, HASVOLD L A, WANG G T, et al. Synthesis and biological evaluation of 1-(2,4,5-trisubstituted phenyl)-3-(5-cyanopyrazin-2-yl)ureas as potent Chk1 kinase inhibitors . Bioorg Med Chem Lett, 2006, 16(8): 2293-2298. TAO Z F, CHEN Z, BUI M H, et al. Macrocyclic ureas as potent and selective Chk1 inhibitors: An improved synthesis, kinome profiling, structure-activity relationships, and preliminary pharma-cokinetics . Bioorg Med Chem Lett,2007, 17(23): 6593-6601. LI G, HASVOLD L A, TAO Z F, et al. Synthesis and biological evaluation of 1-(2,4,5-triSubs-tituted phenyl)-3-(5-cyanopyrazin-2-yl)ureas as potent Chk1 kinase inhibitors . Bioorg Med Chem Lett,2006, 16(8): 2293-2298. ZHAO L Y, ZHANG Y X, DAI C Y, et al. Design, synthesis and SAR of thienopyridines as potent CHK1 inhibitors . Bioorg Med Chem Lett, 2010, 20(24): 7216-7221. DUDKIN V Y, RICKERT K, CHENG W, et al. Pyridyl aminothiazoles as potent inhibitors of Chk1 with slow dissociation rates . Bioorg Med Chem Lett, 2012, 22(7): 2609-2612. JANEKTA J W, ALMEIDA L, ASHWELL S, et al. Discovery of a novel class of 2-ureido thiophene carboxamide checkpoint kinase inhibitors . Bioorg Med Chem Lett, 2008, 18(14): 4242-4248. OZA V, ASHWELL S, BRASSIL P, et al. Discovery of a novel class of triazolones as Checkpoint Kinase inhibitors—Hit to lead exploration . Bioorg Med Chem Lett, 2010, 20(17): 5133-5138. OZA V, ASHWELL S, BRASSIL P, et al. Synthesis and evaluation of triazolones as checkpoint kinase 1 inhibitors . Bioorg Med Chem Lett, 2012, 22(6): 2330-2337. DWYER M P, PARUCH K, LABROLI M, et al. Discovery of pyrazolopyrimidine-based CHK1 inhibitors: A template-based approach—Part 1 .Bioorg Med Chem Lett, 2011, 21(1): 467-470. MATTHEWS T P, MCHARDY T, KLAIR S, et al. Design and evaluation of 3,6-di(hetero)aryl imidazopyrazines as inhibitors of checkpoint and other kinases . Bioorg Med Chem Lett, 2010, 20(14): 4045-4049. HASVOLD L A, WANG L, PRZYTULINSKA M, et al. Investigation of novel 7,8-disubstituted-5, 10-dihydrodibenzo-diazepin-11-ones as potent Chk1 inhibitors . Bioorg Med Chem Lett, 2008, 18(7): 2311-2315.
PDF(2854 KB)

Accesses

Citation

Detail

段落导航
相关文章

/